CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
Valganciclovirdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00006145
NCT00006145Phase 3Completed
CompareCT.gov

A Phase III, Prospective, Randomized, Double-Blind Trial of Valganciclovir Pre-Emptive Therapy for Cytomegalovirus (CMV) Viremia as Detected by Plasma CMV DNA PCR Assay

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Aug 31, 2001·Updated Nov 1, 2021

In Brief

A Phase 3 clinical trial evaluating Valganciclovir for Cytomegalovirus Infections and HIV Infections. Completed, across 57 sites in 2 countries.

Detailed Summary

Cytomegalovirus (CMV) infection is a common opportunistic infection (OI) in HIV patients. The purpose of this study is to find out whether valganciclovir, an antiviral approved by the FDA for the treatment of CMV in the eye, is safe and effective in preventing CMV organ damage in people with HIV.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCytomegalovirus Infections, HIV Infections
CountriesPuerto Rico, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 31, 2001
Enrollment StartAug 1, 2000
Study CompletionFeb 1, 2006
TodayJul 2, 2026
Posted 24.8 years ago

Interventions

Valganciclovirdrug